Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Ilodon is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Iloperidone must be titrated slowly to avoid orthostatic hypotension. Because of this need to titrate slowly, control of symptoms may be delayed during the first 1 to 2 weeks of treatment. Administer Iloperidone orally twice daily, without regard to meals, and titrate the dosage to avoid orthostatic hypotension. For schizophrenia, the starting dosage is 1 mg twice daily and the recommended dosage is 6 mg to 12 mg twice daily. For bipolar mania, the starting dosage is 1 mg twice daily and the recommended dosage is 12 mg twice daily. In children and adolescents, safety and effectiveness have not been established. Iloperidone is not recommended for patients with severe hepatic impairment.
Side Effects
The side effects seen most often (occurring in at least 5% of patients and at least 2 times more frequently than with placebo) were as follows. In schizophrenia: dizziness, dry mouth, tiredness, blocked nose, a drop in blood pressure on standing (orthostatic hypotension), drowsiness, fast heartbeat, and weight gain. In bipolar mania: fast heartbeat, dizziness, dry mouth, raised liver enzymes, blocked nose, weight gain, low blood pressure, and drowsiness.
Cautions & Contraindications
Warnings & Precautions
Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: there is an increased incidence of cerebrovascular adverse reactions, such as stroke and transient ischaemic attack. QT prolongation: Iloperidone prolongs the QT interval and may be associated with arrhythmia and sudden death. Avoid using FANAPT together with other drugs known to prolong QTc. Use caution, and consider adjusting the dose, when prescribing FANAPT with other drugs that inhibit FANAPT metabolism. Monitor serum potassium and magnesium in patients at risk of electrolyte disturbances. Neuroleptic malignant syndrome (NMS): manage by stopping the drug immediately and monitoring the patient closely. Tardive dyskinesia: discontinue treatment if clinically appropriate. Metabolic changes: monitor for hyperglycaemia or diabetes mellitus, dyslipidaemia, and weight gain. Orthostatic hypotension and syncope: monitor heart rate and blood pressure, and warn patients who have known cardiovascular or cerebrovascular disease, or who are at risk of dehydration or syncope. Seizures: use with caution in patients with a history of seizures or with conditions that lower the seizure threshold. Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics. Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider stopping FANAPT if a clinically significant fall in WBC occurs without any other identifiable cause. Priapism: cases have been reported in association with FANAPT treatment. Severe priapism may require surgical intervention. Potential for cognitive and motor impairment: use caution when operating machinery. Intraoperative floppy iris syndrome (IFIS): IFIS during cataract surgery may require changes to the surgical technique.
Contraindications
Known hypersensitivity to Iloperidone or to any ingredient in the formulation.